Navigation Links
Beijing Chaoyang District Court Grants Investigation Letters Against Inverness Medical Beijing, A Subsidiary of Alere Inc.
Date:4/11/2011

BEIJING, April 11, 2011 /PRNewswire-Asia/ -- Chinmax Medical Systems Inc., a leading cardiac biomarker distributor in China announced an update regarding the progress of its lawsuit against Inverness Medical Beijing (IMB), a subsidiary of Alere Inc.(NYSE: ALR).

According to the Complaint, Inverness Medical Beijing secretly imported massive quantities of Triage product and sold the same to Chinmax customers during the period when Chinmax retained the undisputed contractual rights as Alere's exclusive distributor of Triage product for the China market. The Complaint also alleges that IMB violated Chinmax's proprietary rights under the distribution agreement by submitting applications to the State Food and Drug Administration (SFDA) and attempting to change Chinmax's legal status on the SFDA registrations of the Triage products. Chinmax filed suit in Beijing Chaoyang District Court in March 2010, claiming tort damages for unfair competition against Inverness Medical Beijing. Chinmax applied to the court for investigation letters allowing the collection of evidence regarding IMB's sales invoices, importation documents, and SFDA submissions. In recent progress, the Beijing Chaoyang District Court approved Chinmax's application and has now sent investigation letters to China Customs, State Taxation Office, and the SFDA, seeking the relevant documentation. The court is currently in the process of collecting this evidence from the China authorities. Chinmax believes the evidence will support both the China litigation against IMB and the U.S. arbitration Chinmax has filed against Alere San Diego for fraud, breach of contract and unfair competition due to unfair and illegal conduct.

Since 1999, Chinmax has been the exclusive distributor in China of diagnostics products manufactured by Biosite Incorporated (now known as “Alere San Diego”), a world-leading cardiac biomarkers company in San Diego, California, USA. In 2007, Biosite was acquired by Inverness Medical Innovations, Inc. (now known as Alere, Inc. (NYSE: ALR)).  Inverness Medical Beijing, a Chinese subsidiary of Alere, Inc., said the company obtained the right to manage contracts between Biosite and Chinmax in December 2008.


'/>"/>
SOURCE Chinmax Medical Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Tianyins Dr. James Jiayuan Tong is Invited to Speak at the CFO China Summit 2011 on January 19, 2011 at the St. Regis Hotel, Beijing
2. Rodobo International, Inc. to Present at Rodman & Renshaw Conference in Beijing on March 8, 2010
3. Tianyin Pharmaceutical Co., Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing on March 9
4. Nutrastar International, Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing
5. Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai
6. WuXi PharmaTech (NYSE: WX) Holds Its Third Life Science and Chemistry Awards Ceremony in Beijing
7. For the First Time, a Glioma - Brain Cancer - may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing
8. For the First Time, a Glioma ¨C Brain Cancer ¨C may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing
9. China Biologic Products to Attend at Susquehannas Third Annual Beijing Management Summit
10. China-Biotics, Inc. to Attend the SIG 3rd Annual Beijing Management Summit
11. CSOFT Announces Introduction of L10NPRO 3.0 at 6th Annual Worldwide Summit in Beijing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017 /PRNewswire -- WuXi AppTec, ... open-access capability and technology platform, today announced that ... biology focused preclinical drug discovery contract research organization ... become a wholly-owned subsidiary of WuXi, and will ... and providing greater services. The acquisition will further ...
(Date:1/19/2017)... Calif. , Jan. 19, 2017  ArmaGen, ... Mathias Schmidt , Ph.D., as chief executive officer, ... of directors. Dr. Schmidt brings to ArmaGen more than ... the research and development of biotherapeutics and pharmaceuticals. ... executive with the diverse experience and skillset necessary ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... the full spectrum of drug and device development, and Prism Clinical Research ... and clinicians, today announced Verified Clinical Trials (VCT) has been selected ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... interconnect using USB or PCI Express, announced the ZEM5310 USB 3.0 FPGA Module, ... into a compact business-card sized form factor suitable for prototyping, testing, and production-ready ...
Breaking Biology Technology:
(Date:12/15/2016)... "Increase in mobile transactions is driving the growth of ... expected to grow from USD 4.03 billion in 2015 ... of 29.3% between 2016 and 2022. The market is ... smart devices, government initiatives, and increasing penetration of e-commerce ... to grow at a high rate during the forecast ...
(Date:12/8/2016)... Market Research Future published a half cooked research report ... Security and Service Market is expected to grow over the CAGR ... Highlights: ... Mobile Biometric Security and Service Market is ... of authentication and security from unwanted cyber threats. The increasing use ...
(Date:12/7/2016)... -- According to a new market research report "Emotion Detection and ... Recognition), Service, Application Area, End User, And Region - Global Forecast to 2021", ... Billion in 2016 to USD 36.07 Billion by 2021, at a Compound Annual ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):